AbbVie completes $10.9B cash acquisition of Apogee Therapeutics

AbbVie Inc.

Apogee shareholders received $135.11/share cash; total equity value ~$10.9B.
Adds zumilokibart (IL-13 mAb for atopic dermatitis) and APG273 (asthma candidate) to immunology pipeline.
Deal dilutive to adjusted EPS by $0.14 in 2026 and ~$0.46 in 2027; accretion expected from 2032.
AbbVie reaffirms FY2026 adjusted EPS guidance $13.87-$14.07 and Q3 guidance $3.84-$3.88.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.